ReviewPharmaceutics2026
Nanotechnology in Pediatric Neurology: Applications and Innovations.
Review in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanotechnology is rapidly transforming the perspective on pediatric neurology, enabling diagnostic, therapeutic, and monitoring strategies tailored to the unique features of neurological illnesses in children. This review acknowledges the problems caused by delays in diagnosis, the limitations of conventional procedures, and the need for new, focused approaches, highlighting recent advances in nanoscale materials and smart nanocarriers. Specifically, this paper summarizes advances in nanomaterials that can overcome physiological barriers, such as the developing blood-brain barrier (BBB) and age-dependent pharmacokinetics. We discuss innovations in stimuli-responsive delivery systems, theranostic platforms, and multimodal nanohybrids designed for precise targeting and real-time treatment monitoring. Special emphasis is placed on pediatric-specific considerations, including developmental differences in immune and metabolic responses, the necessity for age-adjusted dosing, and the potential long-term safety implications of nanoparticle exposure. Transformative applications are explored in various pediatric neurological conditions, including brain tumors, epilepsy, neurodevelopmental disorders, and rare degenerative diseases, emphasizing both achievements and challenges in translation. This paper evaluates various regulatory, ethical, and societal factors, alongside the integration of converging technologies such as AI-driven nanoparticle optimization, brain organoids, and digital twins to accelerate personalized therapy development. Conclusively, this paper emphasizes the importance of interdisciplinary collaboration, pediatric-focused clinical trial designs, and sustained investment to fully realize the potential of nanotechnology in improving neurological outcomes for children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.